ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / WOK / insiders
NVNO (33) SNOA (34) XAIR (30) TNON (30) ⌘ Pro Terminal →

WORK Medical Technology Group LTD (Class A) (WOK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.00 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.00

WORK Medical Technology Group LTD (Class A) (WOK) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $4.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WOK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (0.00% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, WOK ranks #256 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WOK compare to NVNO and SNOA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WOK?
▼

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $13.9M in revenue (-68.0% YoY), -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.00 (-0.19%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 35.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (16)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3% Base Target
$87780 Bull$1 Base$1 Bear
📬 FREE WOK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WOK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY WOK SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 35.3% FCF Margin ($4.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$1.39-17.3% Next Q
Q2 (-2Q)
56
Grade C$1.15+1.7% Next Q
Q3 (-1Q)
54
Grade C-$1.17-14.5% Next Q
Current
51
Grade D$1.00-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WOK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WOK currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.05) forces dealer call-delta covering toward $87,780.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WOK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WOK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

WOK Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (WOK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on WOK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WOK)

  • ✓Walkthrough of WOK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
WOK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.27%▲ RESISTANCE BREAKOUT
2026-11-03O $1.10H $1.10L $1.00C $1.00VOL 61.2K
RES: $0.82SUP: $0.98SMA50: $1.66SMA200: $60.94
$216,084.8$157,520.1$98,955.3$40,390.5$-18,174.28RES $0.82SUP $0.98$1.002026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WOK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WOK Butterfly Map → + Track WOK →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -68.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on WOK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WOK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WOK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WOK)

Health Care Rank #256 of 1015 ⚔️ NVNO vs WOK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WOK vs. NVNO, SNOA, XAIR, TNON)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, WORK Medical Technology Group LTD (Class A) (WOK) ranks #256 by composite RQD confidence (51/100, grade D) and #953 by equity capitalization ($4.5M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WOK ACTIVE
WORK Medical Technology Group LTD (Class A)
D 51/100 — — — 0.00% $4.5M Benchmark Subject
NVNO
enVVeno Medical Corporation
E 33/100 — — -35.0% +2.08% $4.7M /nvno-vs-wok →
SNOA
Sonoma Pharmaceuticals Inc.
E 34/100 — 38.0% -35.0% 0.00% $5.3M /snoa-vs-wok →
XAIR
Beyond Air Inc.
E 30/100 112.1x 3.3% -35.0% -1.34% $3.7M /xair-vs-wok →
TNON
Tenon Medical Inc.
E 30/100 — 59.8% -35.0% -5.85% $5.5M /tnon-vs-wok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001929783 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported GAAP revenue of $13.9M (-68.0% vs. FY2024 revenue of $43.5M , and +65.8% cumulative change since FY2023) , GAAP net income of -$1.1M, operating cash flow of $6.2M, and free cash flow of $4.9M (+142.9% YoY). On the balance sheet, WOK closed FY2025 with $33.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $13.9M -$1.1M $6.2M $4.9M $33.2M —
FY2024 (FY) 2024-09-30 $43.5M -$3.5M -$2.2M -$11.5M — —
FY2023 (FY) 2023-09-30 $8.4M $112.0K $2.2M $2.2M — —

3. WOK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (0.00% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, WOK ranks #256 in composite RQD confidence.

How does WOK compare to NVNO and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WOK?

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $13.9M in revenue (-68.0% YoY), -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WOK trading relative to its 50-day, 200-day, and 52-week technical levels?

WOK last traded at $1.00 (0.00% on volume of 31,974 shares), positioning the stock -39.76% below its 50-day simple moving average ($1.66) and -98.36% below its 200-day simple moving average ($60.94). Across its 52-week range of $1.00 to $83,600.00, WOK sits at the 0.0% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.13).

Direct Sub-Reports: WOK RQD Cockpit WOK 12M Forecast WOK Earnings & Move WOK Dividends & DRIP WOK Insiders & 13F WOK Whale Options WOK Profit Sankey WOK News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ SEC XBRL & RQD VERIFIED

WOK — WORK Medical Technology Group LTD (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

WORK Medical Technology Group LTD (Class A) (WOK) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.00 (0.00% 1D, market capitalization $4.5M).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

WORK Medical Technology Group LTD (Class A) is a NASDAQ-listed issuer classified in the Health Care sector and the Medical/Dental Instruments industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported $13.9M in annual revenue (up from $43.5M in FY2024, -68.0% YoY) and -$1.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.4M revenue, $112.0K net income) through FY2025, WOK scaled operating cash flow to $6.2M and free cash flow to $4.9M, backed by $33.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 51/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.00 – $83,600.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated names for WOK.

  • Key Question #1: Can WOK sustain or expand its — operating margin and — ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $13.9M and free cash flow of $4.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is WOK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

WOK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for WORK Medical Technology Group LTD (Class A) (WOK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WOK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WOK Bull vs. Bear Conversation Board — What's Your Call at $1.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WOK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on WOK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $1.25 (+25.0%)
📌 Pinned Debate

Balance-sheet pillar scores 13/20 with Altman Z of 2.5 and Debt/Equity of 0.5, and FY 2025 FCF of $4.9M was positive after a prior-year

Don't sleep on WOK's setup in Health Care. Balance-sheet pillar scores 13/20 with Altman Z of 2.5 and Debt/Equity of 0.5, and FY 2025 FCF of $4.9M was positive after a prior-year deficit.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (51/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — WOK's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.85 (-15.0%)
Spot @ $1.00

ROIC and FCF yield are both 0% and reported revenue is $0.0M in every period, while whale 13F flow scores only 3/20.

Here is the bear case nobody on the bull side wants to address on WOK: ROIC and FCF yield are both 0% and reported revenue is $0.0M in every period, while whale 13F flow scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%